DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma.

doi:10.1038/s41467-026-70120-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma.

Nature communications - 7 Mar 2026

Renouf Daniel J, Topham James T, Loree Jonathan M, Schaeffer David F, Knox Jennifer J, Kavan Petr, Jonker Derek, Welch Stephen, Couture Felix, Lemay Frederic, Tehfe Mustapha, Harb Mohammed, Aucoin Nathalie, Ko Yoo-Joung, Tang Patricia A, Ramjeesingh Ravi, Meyers Brandon M, Kim Christina A, Du Pan, Jia Shidong, Karasinska Joanna M, Gill Sharlene, Tu Dongsheng, O'Callaghan Chris J

Abstract excerpt

The CCTG PA.7 study was a randomized phase II trial comparing chemotherapy with and without dual immune checkpoint inhibition in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). In follow-up to the published primary results of the trial, the analysis herein focused on long-term survival and exploratory analysis.Plasma sequencing analysis identified concurrent mutations in DNA damage repair genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Pancreatic Ductal

Share to Deoxycytidine

Share to Gemcitabine

Share to Paclitaxel

Share to Pancreatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41794844
DOI: 10.1038/s41467-026-70120-z
PMCID: PMC13096329

Genes

ATM
BRCA1
FANCA
POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma.PMID 41794844Read ↗

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor EffectivenessSemantic proximity Read ↗

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialSemantic proximity Read ↗

Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.Semantic proximity Read ↗

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.Semantic proximity Read ↗

Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.Semantic proximity Read ↗

Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an open-label, phase Ib/II study and investigation of potential biomarkersSemantic proximity Read ↗

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapySemantic proximity Read ↗

Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?Semantic proximity Read ↗

PD-1 blockade plus capecitabine as curative-intent treatment for tumor mutational burden-high multi-metastatic pancreatic ductal adenocarcinoma: A case reportSemantic proximity Read ↗

Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor ProgramSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.